Sports Medicine Market to Grow 7.4% CAGR by 2022

Posted On October 6, 2017 By OrthoSpineNews In Sports Medicine /

PUNE, India, October 6, 2017 /PRNewswire/ —

The global sports medicine market will reach $8.24 billion by 2022 from $5.78 billion in 2017 at a CAGR of 7.4% during (2017-2022) driven by increasing incidences of sports injuries, continuous influx of new products and treatment modalities, and development in the field of regenerative medicine, while in 2017, North America accounted largest share of the said market followed by Europe, APAC and RoW according to RnRMarketResearch.

Browse 103 Market Data Tables and 32 Figures spread through 169 Pages and in-depth TOC on “Sports Medicine Market by Product (Implants, Arthroscopy, Prosthetic, Orthobiologics, Braces, Compression Clothing, Physiotherapy (Thermal, Ultrasound), Bandages & Tapes), Application (Knee, Shoulder, Elbow) – Global Forecast to 2022“ http://www.rnrmarketresearch.com/sports-medicine-devices-market-by-products-application-2012-2017-bone-cartilage-ligament-tendon-reconstruction-repair-braces-hot-cold-therapy-topical-pain-relief-compression-clothing-market-report.html .

The key players in the global sports medicine market are Arthrex, (US), Smith & Nephew (UK), DePuy Synthes (US), Stryker (US), CONMED (US), Zimmer Biomet (US), Breg (US), DJO Global (US), Mueller Sports (US), Wright Medical Group (US), Medtronic (Ireland), RTI Surgical (US), and Performance Health International (US).

Based on application, the sports medicine market is segmented into shoulder injuries, foot and ankle injuries, elbow and wrist injuries, back and spine injuries, hip and groin injuries, knee injuries, and other injuries (head, face, and finger injuries). The elbow and wrist injuries segment is expected grow at the highest CAGR during the forecast period. This growth can be attributed to the increasing number of injuries in sports like rowing, racquet sports, and golf, where there is a repetitive overuse of elbow and wrists.

Make an Inquiry on Sports Medicine Market – Global Forecast to 2022 research report at http://www.rnrmarketresearch.com/contacts/inquire-before-buying?rname=80170 .

On the basis of product, the sports medicine market is segmented into body reconstruction products, body support & recovery products and accessories. In 2017, the body reconstruction products segment is expected to account for the largest share of the market. The large share of this segment can primarily be attributed to the wide usage of implants and arthroscopy devices by sports medicine surgeons and orthopedic surgeons for sports-related injuries. The body reconstruction products segment is further segmented into implants, fracture & ligament repair devices, arthroscopy devices, prosthetics, and orthobiologics.

Asia Pacific is expected to witness the highest sports medicine market growth during 2017 to 2022. The influx of international players, government initiatives to promote sports medicine, and collaborations for sports medicine research are the key factors responsible for the growth of this market in the APAC region.

Inquire for Discount on “Sports Medicine Market – Global Forecast to 2022“ research report at http://www.rnrmarketresearch.com/contacts/discount?rname=80170 .

The report analyzes the sports medicine market and aims at estimating market size and future growth potential of this market based on various segments such as product, application, and region. In 2017, the fracture & ligament repair devices segment is expected to account for the largest share of the market. The high incidence of fractures and ligament tears in sports is expected to drive the market for fracture and ligament repair devices. The orthobiologics segment is expected to register the highest CAGR during the forecast period. The recent developments in regenerative medicine, allografts, and stem cell therapy to treat broken bones are expected to drive the growth of the orthobiologics market.

Break of primary participants was as mentioned below:

By Company Type: Tier 1-55%, Tier 2-25% and Tier 3-20%
By Designation: C-level-43%, Director Level-32%, Others-25%
By Region: North America-38%, Europe-23%, Asia Pacific-29%, RoW-10%

Another research titled Orthobiologics Market Global Forecast to 2022 says, the global orthobiologics market is projected to reach $6.06 billion by 2022 from $4.66 billion in 2017, at a CAGR of 5.4%. The PRP segment is expected to grow at the highest rate during the forecast period. The spinal fusion segment is expected to grow at the highest CAGR. Hospitals, orthopedic clinics, and ambulatory care centres are expected to be the fastest-growing segment. Asia Pacificis expected to register the highest growth rate in the orthobiologics market. Companies such as DePuy Synthes, Medtronic, Stryker, Zimmer Biomet, Harvest Technologies, Globus Medical have been profiled in this 159 pages research report available athttp://www.rnrmarketresearch.com/orthobiologics-market-by-product-viscosupplementation-synthetic-orthobiologics-dbm-bmp-prp-bmac-allograft-application-fracture-recovery-osteoarthritis-spinal-fusion-soft-tissue-end-user-hospitals-as-st-to-2022-market-report.html .

Explore more reports on Medical Devices Market athttp://www.rnrmarketresearch.com/reports/life-sciences/medical-devices .

About Us:

RnRMarketResearch.com is your single source for all market research needs. Our database includes 500,000+ market research reports from over 100+ leading global publishers & in-depth market research studies of over 5000 micro markets. With comprehensive information about the publishers and the industries for which they publish market research reports, we help you in your purchase decision by mapping your information needs with our huge collection of reports.

Contact:
Hrishikesh Patwardhan
2^nd Floor, Metropole Building,
Next to Inox Theatre,
Bund Garden Road, Pune – 411001.
Maharashtra, India.
+1-888-391-5441
sales@rnrmarketresearch.com

Connect with Us:

G+ / Google Plus: https://plus.google.com/104156468549256253075/posts

Twitter: https://twitter.com/RnRMR

Facebook: https://www.facebook.com/pages/RnR-Market-Research/413488545356345

RSS / Feeds: http://www.rnrmarketresearch.com/feed

SOURCE RnRMarketResearch

Researchers at HSS Receive Grants to Study Bone Stress Injuries

Posted On September 12, 2017 By OrthoSpineNews In Financial, Sports Medicine /

NEW YORK, Sept. 12, 2017 /PRNewswire-USNewswire/ — Two research teams at Hospital for Special Surgery (HSS) have been awarded grants by the NBA and GE Healthcare Orthopedics and Sports Medicine Collaboration. This strategic partnership between NBA and GE Healthcare was launched to collaborate with leading clinical researchers to address the prevention, diagnosis and treatment of musculoskeletal injuries affecting NBA players and everyday athletes.

A team led by Brett Toresdahl, MD, primary care sports medicine physician at HSS, received a grant of nearly $300,000that will go towards investigating the use of ultrasound imaging to monitor healing and guide readiness of return to play in athletes with bone stress injuries.

Bone stress injuries of the lower leg and foot are common among elite basketball players and can require a long period of rest in order to fully recover. Determining when a player is ready to return to play has historically been difficult as it relies primarily on a player’s symptoms since signs of healing are not reliably seen with standard imaging (such as MRI and X-ray).

“There is little known about the connection between ultrasound findings, symptoms, and readiness for return to sport for athletes with bone stress injuries,” said Dr. Toresdahl, principle investigator of the study. “Our goal is to evaluate the use of serial ultrasound to assess bony healing to optimize treatment and more accurately predict readiness for return-to-play.”

The investigators will recruit adults between 18 and 50 years of age who have a bone stress injury in the lower leg or foot as a result of sport or exercise and diagnosed by MRI.

Participants will receive standard treatment of rest and crutches, splint and/or walking boot. An ultrasound will be performed every two weeks for 12 weeks at the site of the injury. Simultaneously, patients will be tracking their pain, activity and return to activity. A radiologist will grade the amount and appearance of bony callus formation and then a repeat MRI will be performed at 12 weeks.

“Our findings could provide doctors with a new way to guide athletes to safely return to play after a bone stress injury with a minimal risk of re-injury,” added Dr. Toresdahl.

The Athlete’s Foot

The other grant received by HSS went to a team led by Martin O’Malley, MD, foot and ankle surgeon at HSS. This $100,000 grant will be used to assess risk factors and intervention strategies for fifth metatarsal stress fractures, the most common type of stress fractures for basketball players. These fractures can be difficult to treat, leading to long-term consequences for an elite basketball player.

“Currently, there is limited knowledge on how to identify athletes who are at a high risk for a fifth metatarsal stress fracture,” said Dr. O’Malley, principle investigator of this study. “Additionally, we don’t have a clinical understanding on how to intervene before such injury occurs.”

This research will utilize data from the screening of collegiate and professional basketball players to identify factors of foot structure that are common in those who sustained a fifth metatarsal injury. The investigators will employ a specialized robotic device that will stimulate walking and jumping in cadavers to find features that increase the mechanical burden on this bone.

Testing will also be done to assess the ability of intervention strategies to reduce this mechanical burden and thus, the risk of injury.

“We hope to gain objective biomechanical evidence that will rationalize intervention strategies such as orthotic devices and targeted muscle activation in order to reduce risk of injury and re-injury,” added Dr. O’Malley.

About Hospital for Special Surgery
Hospital for Special Surgery (HSS) is the world’s leading academic medical center focused on musculoskeletal health. HSS is nationally ranked No. 1 in orthopedics and No. 3 in rheumatology by U.S. News & World Report (2017-2018), and is the first hospital in New York State to receive Magnet Recognition for Excellence in Nursing Service from the American Nurses Credentialing Center four consecutive times. HSS has one of the lowest infection rates in the country. HSS is an affiliate of Weill Cornell Medical College and as such all Hospital for Special Surgery medical staff are faculty of Weill Cornell. The hospital’s research division is internationally recognized as a leader in the investigation of musculoskeletal and autoimmune diseases. HSS has locations in New York, New Jersey and Connecticut.
www.hss.edu

SOURCE Hospital for Special Surgery

AAEAAQAAAAAAAAJYAAAAJDRjNThjOTU3LWQwZDAtNDA2ZS1iMWM0LWY4NjZhZjJhMThiOA.png

InVivo Therapeutics Announces Publication in Neurosurgery of Lifetime Hospitalization Costs for Thoracic Spinal Cord Injury Patients by Severity Grade

Posted On September 6, 2017 By OrthoSpineNews In Financial, Neuro, Sports Medicine /

September 05, 2017

CAMBRIDGE, Mass.–(BUSINESS WIRE)–InVivo Therapeutics Holdings Corp. (NVIV) today announced the publication of an article titled “Relationship of American Spinal Injury Association Impairment Scale Grade to Post-injury Hospitalization and Costs in Thoracic Spinal Cord Injury” in the journal Neurosurgery. Neurosurgery is the official journal of the Congress of Neurological Surgeons. The article estimates the lifetime economic costs associated with hospitalizations in relation to American Spinal Injury Association Impairment Scale (AIS) grade. AIS grades are widely-used measures of spinal cord injury (SCI) severity that range from AIS A (complete) to AIS E (normal). The article concludes that patients with less severe thoracic SCI, as reflected in AIS grade, spend fewer days hospitalized over their lifetimes, leading to lower costs of inpatient care. Therefore, therapies improving AIS grade following thoracic SCI may provide cost savings in addition to addressing substantial unmet need.

Specifically, the article reports a lifetime net present value cost savings of about $72,000 for patients with thoracic AIS B SCI as compared to patients with thoracic AIS A SCI, and of about $132,500 for patients with thoracic AIS C SCI as compared to patients with thoracic AIS A SCI.

Dr. Steven Kirshblum, Director of the Spinal Cord Injury Program at the Kessler Institute for Rehabilitation and one of the authors of the article, said “This article is a valuable contribution to the literature regarding the economic burden of spinal cord injury. This is one of the first articles to evaluate a key component of long-term treatment cost by AIS grade and level of injury and establishes that improvement in AIS grade may be associated with cost savings.”

“We are very pleased to have our first publication regarding the financial burden of illness of spinal cord injury and the potential economic impact of patients converting to less severe AIS grade,” Mark Perrin, InVivo’s CEO and Chairman, said. “This publication focuses on the re-hospitalization costs associated with patients with different AIS grades, but there are also many other direct healthcare costs and indirect costs, such as lost wages, associated with SCI. In the future, we plan to continue to evaluate the burden of illness by AIS grade and to publish additional findings. As we work to complete the INSPIRE study of the Neuro-Spinal Scaffold™, we anticipate that these publications will serve as foundational components of our commercial launch strategy.”

The publication is now available electronically through Neurosurgery prior to print publication at: https://doi.org/10.1093/neuros/nyx425.

About InVivo Therapeutics

InVivo Therapeutics Holdings Corp. is a clinical-stage biomaterials and biotechnology company with a focus on treatment of spinal cord injuries. The company was founded in 2005 with proprietary technology co-invented by Robert Langer, Sc.D., Professor at Massachusetts Institute of Technology, and Joseph P. Vacanti, M.D., who then was at Boston Children’s Hospital and who now is affiliated with Massachusetts General Hospital. In 2011, the company earned the David S. Apple Award from the American Spinal Injury Association for its outstanding contribution to spinal cord injury medicine. In 2015, the company’s investigational Neuro-Spinal Scaffold™received the 2015 Becker’s Healthcare Spine Device Award. The publicly-traded company is headquartered in Cambridge, MA. For more details, visit www.invivotherapeutics.com.

Safe Harbor Statement

Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements within the meaning of the federal securities laws. These statements can be identified by words such as “believe,” “anticipate,” “intend,” “estimate,” “will,” “may,” “should,” “expect,” “designed to,” “potentially,” and similar expressions, and include statements regarding the safety and effectiveness of the Neuro-Spinal Scaffold™, the status of the clinical program, and the company’s plans regarding future publications. Any forward-looking statements contained herein are based on current expectations, and are subject to a number of risks and uncertainties. Factors that could cause actual future results to differ materially from current expectations include, but are not limited to, risks and uncertainties relating to the company’s ability to successfully open additional clinical sites for enrollment and to enroll additional patients; the timing of the Institutional Review Board process; the expected benefits and efficacy of the company’s products and technology in connection with the treatment of spinal cord injuries; the availability of substantial additional funding for the company to continue its operations and to conduct research and development, clinical studies and future product commercialization; and other risks associated with the company’s business, research, product development, regulatory approval, marketing and distribution plans and strategies identified and described in more detail in the company’s Quarterly Report of the three months ended June 30, 2017, and its other filings with the SEC, including the company’s Form 10-Qs and current reports on Form 8-K. The company does not undertake to update these forward-looking statements.

Contacts

InVivo Therapeutics Holdings Corp.
Heather Hamel, 617-863-5530
Investor Relations
Investor-relations@invivotherapeutics.com

1st Patient Recruited in Orthocell Ortho-ATI® Shoulder Tendon Study

Posted On September 5, 2017 By OrthoSpineNews In Sports Medicine /

September 04, 2017

PERTH, Australia–(BUSINESS WIRE)–Regenerative medicine company Orthocell Limited (ASX:OCC) today announced that it has recruited and treated its first patient in a randomised, controlled clinical trial of Ortho-ATI® versus corticosteroid injection, for the treatment of rotator cuff tendinopathy and tear in the shoulder.

Rotator cuff tendinopathy and tear (which manifests as severe shoulder pain) is a common and often difficult injury to treat and affects more than 50% of adults over 50 years of age. Rotator cuff injuries may lead to considerable disability, reduced quality of life, and absenteeism from work, and are a significant burden on healthcare resources. This burden is expected to increase as the population ages, and as a result, new treatments are required that address the underlying pathology of the injury, not just the symptoms.

The objective of this clinical trial is to assess the effectiveness of Autologous Tenocyte Injection (Ortho-ATI®) compared to corticosteroid injection in the treatment of rotator cuff tendinopathy and tear. To be eligible for the trial, patients must have failed previous conservative treatment options, including previous injection treatment and physiotherapy. The trial will be led by Clinical Professor Allan Wang, President of the Australian Elbow and Shoulder Society, Clinical associate Professor Bill Breidahl and Professor Ming Hao Zheng at the University of Western Australia (UWA).

Orthocell Managing Director Paul Anderson said: “Demonstrating the efficacy of Ortho-ATI® for the treatment of rotator cuff tendinopathy is an important element of our product development and partnering strategy. We expect results to show Ortho-ATI® is a durable and effective treatment for degenerative shoulder injuries.”

In studies conducted by Orthocell to date, Ortho-ATI® has been shown to be a cost effective long-term and durable, non-surgical solution for difficult to treat tendon injuries. Ortho-ATI® is available in Australia, New Zealand, and Hong Kong with regulatory oversight for patients who have failed conservative treatment options such as corticosteroid injections and exercise programs and have ongoing symptoms.

About Orthocell Limited

Orthocell is a regenerative medicine company developing products for the repair of a variety of tendon, cartilage and soft tissue injuries. Orthocell’s portfolio of products include TGA-licensed cell therapies Autologous Tenocyte Implantation (Ortho-ATI®) and Autologous Chondrocyte Implantation (Ortho-ACI®), which aim to regenerate damaged tendon and cartilage tissue. The Company’s other major product is Celgro®, a collagen medical device which facilitates tissue repair and healing in a variety of orthopaedic, reconstructive and surgical applications and is being readied for first regulatory approvals.

For more information on Orthocell, please visit www.orthocell.com.au or follow us on Twitter @Orthocellltd and Linkedin www.linkedin.com/company/orthocell-ltd

Contacts

General enquiries
Orthocell Limited
Paul Anderson, +61 8 9360 2888
Managing Director
paulanderson@orthocell.com.au
or
Investor and Media enquiries
WE Buchan
Ben Walsh, + 61 411 520 012
bwalsh@buchanwe.com.au

Seven of Colorado’s Top Private Orthopedic Practices Come Together to Form Orthopedic Centers of Colorado, Now the State’s Largest Practice

Posted On August 31, 2017 By OrthoSpineNews In Extremities, Spine, Sports Medicine, Top Stories /

DENVER, Aug. 31, 2017 /PRNewswire/ — Fifty-six of Colorado’s top orthopedic physicians, across seven practices, have united under a common vision of improving outcomes, efficiency, cost, and quality to form Orthopedic Centers of Colorado, LLC (OCC). With 19 offices across the Denver metro area, the combined practice is the largest provider of orthopedic and musculoskeletal care in the state.

The seven practices coming together as Orthopedic Centers of Colorado, LLC are:

Advanced Orthopedic & Sports Medicine Specialists P.C.
Colorado Orthopedic Consultants, P.C.
Denver Spine Surgeons, LLC
Denver-Vail Orthopedics, P.C.
Hand Surgery Associates, P.C.
Orthopedic Associates, LLC
Peak Orthopedics & Spine, PLLC

In a market where just 33 percent of physicians work in independent practice, down from 48 percent in 2012, this formation represents a physician-driven commitment to the private-practice model of medicine.

“The private-practice model has proven to deliver a higher level of quality at a more competitive price,” said Davis Hurley, MD, president of Orthopedic Centers of Colorado. “Patients will continue to benefit from the more personalized approach that private practice delivers to accommodate each patient’s needs.”

As a physician-driven organization, OCC will remain nimble enough to adapt to the ever-changing healthcare landscape, and emerge as pioneers in improved patient outcomes and reduced costs, while maintaining strong personal relationships with the patients from the communities we serve.

The seven practices will begin operating as Orthopedic Centers of Colorado on September 1, 2017. Patients of the practices will see no interruption in their care and services and will begin to see the OCC name on patient communications.

About Orthopedic Centers of Colorado, LLC
The number one choice for orthopedic, hand and spine health in Colorado and the Rocky Mountains, Orthopedic Centers of Colorado is an independent group of 56 physicians focused on patient specific care, quality outcomes, value and continuous improvement. We’ve assembled the best doctors across nearly 30 areas of expertise including Colorado’s best sports medicine and orthopedic physicians. Patients can visit any of our 19 convenient locations for care from doctors who believe quality patient care starts with a great patient experience. Learn more at orthocentersco.com

SOURCE Orthopedic Centers of Colorado, LLC

phan-sun-o-dau-goi-bi-thuong-ton-cung-la-nguyen-nhan-gay-dau-dau-goi.jpg

Global Cartilage Repair Market 2017-2021 with Acelity, DePuy Synthes, Stryker & Smith & Nephew Dominating

Posted On August 31, 2017 By OrthoSpineNews In Sports Medicine /

DUBLIN, August 31, 2017 /PRNewswire/ —

The “Global Cartilage Repair Market 2017-2021” report has been added to Research and Markets’ offering.

The global cartilage repair market to grow at a CAGR of 11.59 % during the period 2017-2021.

The treatment of articular cartilage has evolved tremendously in the past decade. Reparative and restorative methods have been developed to address the significant source of morbidity in the young and active patients. Articular cartilage injury can be focal, which is localized or systemic. Procedures are being developed not only to alleviate the symptoms associated with articular cartilage defects but also to limit the progression of cartilage damages into degenerative diseases.

According to the report, one of the major drivers for this market is Rising incidence of accidental injuries. Globally, the road traffic injuries are increasing, with post complicated symptoms such as weakening of tendons, cartilage tear, and orthopedic issues.

The latest trend gaining momentum in the market is Gene therapy and stem cell therapy. Gene therapy is one of the promising fields in the cartilage repair. Many clinical studies have been performed for cartilage repair. The researchers are trying to develop gene therapy for cartilage repair and currently been investigated for clinical application.

Further, the report states that one of the major factors hindering the growth of this market is Product side effects. Surgeons use cartilage repair products such as tissue scaffold to improve the recovery. These products once grafted in the body may cause serious complications, resulting in their increased scrutiny for safety and efficacy. In many autologous chondrocyte implantation, there were common complications such as graft rejection, symptomatic hypertrophy, disturbed fusion and delamination.

Key vendors

Acelity
DePuy Synthes
Stryker
Smith & Nephew

Other prominent vendors

AlloSource
Bio-Tissue
CellGenix
Collagen Solutions
Geistlich Pharma
Orteq
RTI Surgical
TORNIER
Vericel
XTANT MEDICAL

Key Topics Covered:

Executive Summary
Scope Of The Report
Research Methodology
Introduction
Market Landscape
Market Segmentation By Product
Market Segmentation By End-User
Geographical Segmentation
Drivers And Challenges
Market Trends
Vendor Landscape
Key Vendor Analysis
Appendix

For more information about this report visit https://www.researchandmarkets.com/research/sng3nx/global_cartilage

Media Contact:

Research and Markets
Laura Wood, Senior Manager
press@researchandmarkets.com

For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900

U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716

SOURCE Research and Markets

Tiny cameras to help AHN doctors evaluate damaged knees

Posted On August 30, 2017 By OrthoSpineNews In Sports Medicine /

Aug. 29, 2017 – BEN SCHMITT

Highmark Health and Allegheny Health Network are exploring handheld diagnostic technology that could one day reduce the need for MRI in diagnosing some knee injuries, such as meniscal tears.

The health care networks on Tuesday announced a collaboration with medical device company Trice Medical to evaluate a new imaging tool called mi-eye, which allows doctors to view knee joints from their offices.

The arthroscopic device provides the ability to look inside joints for signs of wear.

“I think in the select patient, this definitely has a role to play, and it will save not only time but money to the system,” said Dr. Sam Akhavan, an AHN orthopedic surgeon who is participating in the study. “Traditionally, with joint injuries, the diagnostic process can span several weeks, often including an in-office physical exam, followed by an MRI, and then a follow-up consultation and surgery if needed.”

The study will look at the effectiveness of using the device to diagnose meniscal tears on a patient’s initial visit, possibly saving time and money.

Akhavan has enrolled six patients and expects to work with 100 before issuing a final analysis.

READ THE REST HERE

Fig-4-Stryker-C-system-illustrating-a-bridging-external-fixator-used-for-distal-radius.png

Global Trauma Fixation Devices Market 2017-2021 with Stryker, Zimmer Biomet & Smith & Nephew Dominating – Research and Markets

Posted On August 22, 2017 By OrthoSpineNews In Extremities, Sports Medicine /

August 21, 2017

DUBLIN–(BUSINESS WIRE)–The “Global Trauma Fixation Devices Market 2017-2021” report has been added to Research and Markets’ offering.

The global trauma fixation devices market to grow at a CAGR of 7.29% during the period 2017-2021.

Global Trauma Fixation Devices Market 2017-2021, has been prepared based on an in-depth market analysis with inputs from industry experts. The report also includes a discussion of the key vendors operating in this market. To calculate the market size, the report considers the sales and value of the trauma fixation devices market.

According to the report, one of the major drivers for this market is Sports injuries. Sports injuries are common among athletes. According to the CDC, in 2011, sports-related injuries resulted in 3.2 million visits to the emergency room (ER) for children below the age of 19.

The latest trend gaining momentum in the market is Technological advancements. Due to the growing demand for trauma fixation devices, companies are developing technologically advanced products to improve their market share.

The product is Conformité Européene (CE) approved for sales in the US. Similarly, bioresorbable plates, pins, and screw implants are widely used for fracture fixation in orthopedic surgeries and trauma care. These bioresorbable products dissolve in the human body. Hence, operations to remove the synthetic material are not required. They also do not corrode or accumulate metals in the tissue.

Further, the report states that one of the major factors hindering the growth of this market is Complications associated with trauma fixation devices. Trauma fixation devices can cause several complications. Surgical procedures that use trauma fixation devices can cause neurological or soft tissue damage, which can lead to paralysis. In some cases, bones take longer time to fuse with the implants. Sometimes, they might not even fuse. Such complications could require corrective surgeries.

Key vendors

Stryker
Zimmer Biomet
Smith & Nephew

Other prominent vendors

Auxein Medical
Brace Orthopaedic
CONWELL MEDICAL
Bioretec
Citieffe
Invibio
B. Braun Melsungen
ReWalk Robotics
NuVasive
FirstRay
OMNI
Orthopeadic Implant Company
PAVIS

Key Topics Covered:

Part 01: Executive summary

Part 02: Scope of the report

Part 03: Research Methodology

Part 04: Introduction

Part 05: Market landscape

Part 06: Segmentation by product type

Part 07: Segmentation by end-user

Part 08: Segmentation by geography

Part 09: Drivers and challenges

Part 10: Market trends

Part 11: Vendor landscape

Part 12: Key vendor analysis

Part 13: Appendix

For more information about this report visit https://www.researchandmarkets.com/research/kcpncl/global_trauma

Contacts

Research and Markets
Laura Wood, Senior Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
Related Topics: Orthopedic Devices

The New York Cosmos Announce Partnership With Hospital for Special Surgery (HSS)

Posted On August 18, 2017 By OrthoSpineNews In Sports Medicine /

NEW YORK, Aug. 16, 2017 /PRNewswire-USNewswire/ — The New York Cosmos announced today that Hospital for Special Surgery (HSS) will be the team’s official hospital. The new multi-year partnership provides the Cosmos access to one of the world’s leading centers for orthopedics and sports medicine. With this partnership, the Cosmos have officially named HSS physician Danyal H. Nawabi, M.D., as the Medical Director/Head Orthopedic surgeon for the team.

“Hospital for Special Surgery is a world leader in orthopedic care and the New York Cosmos are proud to enter into a partnership with them,” said Cosmos Chief Operating Officer, Erik Stover. “With Dr. Nawabi serving as the team’s Medical Director, we are ensuring that our players will receive nothing but the best medical coverage to help maintain a healthy team and provide a quick return to the field when injuries occur.”

“I’ve had the great experience of being involved with the English Premier League and Major League Soccer, and have always had an affinity for the game of soccer and a passion for caring for high performance athletes,” said Dr. Nawabi. “Now as a sports medicine surgeon at HSS it’s my privilege to oversee player care for the New York Cosmos and work with athletic trainers and coaches to keep the team safe and performing optimally on the field.”

Dr. Nawabi is an attending orthopedic surgeon on the Sports Medicine Service at HSS, specializing in knee, shoulder, and hip surgery, performing both arthroscopic and joint replacement surgeries. He completed his medical training at Oxford University in England and residency in orthopedic surgery on the prestigious Percivall Pott Rotation in London. Dr. Nawabi completed his fellowship in sports medicine at HSS and received additional training in sports knee and shoulder surgery while treating elite soccer athletes from the English Premier League and the MLS, including stints with Chelsea FC, West Ham FC, and the New York Red Bulls.

Dr. Nawabi will be joined by fellow HSS colleagues Brett Toresdahl, M.D., primary care sports medicine physician, and Mark Drakos, M.D., foot and ankle surgeon, who will serve as team physicians for the Cosmos. Together, they will provide orthopedic consultation services and oversee the rehabilitation of sports injuries and conditions at the Cosmos’ training facility, as well as at their home field, MCU Park, in Brooklyn.

HSS has been ranked the No. 1 hospital in the country for orthopedics for the eighth consecutive year by U.S. News & World Report. Doctors and therapists from HSS have the distinction of being the team physicians and athletic trainers for some of the most recognized professional sports teams and organizations including the Brooklyn Nets, the New York Knicks, the New York Giants, the New York Mets, the New York Rangers, the New York Red Bulls, UFC, USA Basketball and the FIFA Medical Centre of Excellence among many others.

About The New York Cosmos
The New York Cosmos are the reigning champions of the NASL and the most recognized American soccer brand in the world. Since beginning play at Yankee Stadium in 1971, the iconic club has won a record total of 8 professional soccer championships and brought some of the biggest stars in international soccer to the USA including Pelé, Franz Beckenbauer, Giorgio Chinaglia, Carlos Alberto, and more recently, Raúl and Marcos Senna. With the move to MCU Park in Brooklyn’s historic Coney Island district for the 2017 season, the Cosmos are now based within New York City for the first time in 41 years. For more information on the New York Cosmos, please visit nycosmos.com, join us on Facebook and follow us on Twitter and Instagram (@NYCosmos).

About Hospital for Special Surgery
Hospital for Special Surgery (HSS) is the world’s leading academic medical center focused on musculoskeletal health. HSS is nationally ranked No. 1 in orthopedics and No. 3 in rheumatology by U.S. News & World Report (2017-2017), and is the first hospital in New York State to receive Magnet Recognition for Excellence in Nursing Service from the American Nurses Credentialing Center four consecutive times. HSS has one of the lowest infection rates in the country. HSS is an affiliate of Weill Cornell Medical College and as such all Hospital for Special Surgery medical staff are faculty of Weill Cornell. The hospital’s research division is internationally recognized as a leader in the investigation of musculoskeletal and autoimmune diseases. HSS has locations in New York, New Jersey and Connecticut.
www.hss.edu

SOURCE Hospital for Special Surgery

Renowned Orthopaedic Specialists Publish First Collection of Rebound Bracing Clinical Articles

Posted On August 16, 2017 By OrthoSpineNews In Sports Medicine, Top Stories /

August 15th, 2017

A group of internationally recognized orthopaedic surgeons has published the first collection of clinical cases utilizing Rebound® braces from Össur. The innovative Rebound line includes indication-specific Functional Healing braces designed to optimize patient healing while maintaining function and mobility.

“We are gratified that some of the world’s most respected thought-leaders in orthopaedic surgery have contributed these clinical evaluations of Rebound bracing,” said Dr. Axel Schulz, Medical Director for Össur, the global medical technology leader renowned for its advanced prosthetic and orthopaedic innovations. “Their experience will be very helpful in formulating longer-term clinical protocols for these technologies, which have been specifically designed to help accelerate recovery from PCL, ACL and cartilage-based knee injuries.”

LaPrade Case Demonstrates Rebound PCL’s Effectiveness

The Rebound PCL Brace from Össur is the world’s first dynamic force brace for rehabilitating posterior cruciate ligament (PCL) ruptures. It is part of the Functional Healing® line of innovative indication-specific, dynamic orthopaedic solutions intended to optimize healing while maintaining patient function and mobility.

Össur’s Rebound product family is built on decades of experience and designed to protect bone and soft tissue during healing through innovative technology and proven biomechanical approaches. Rebound PCL, the world’s first and only dynamic force brace for rehabilitating posterior cruciate ligament (PCL) ruptures, reflects the company’s Functional Healing approach to orthopaedic innovation, which focuses on developing proprietary technologies according to specific indication-based protocols and clinically relevant outcomes.

In his case study, Robert LaPrade, M.D., Ph.D., Complex Knee and Sports Medicine Surgeon at The Steadman Clinic, reports that use of the Rebound PCL brace helped aid an adult male gymnast recover after double bundle PCL reconstruction, a complete anatomic posterolateral corner knee reconstruction and a medial meniscus root repair following a severe varus noncontact injury. With full restoration of knee motion and complete healing of his PCL and PCL reconstructions, the patient had an excellent outcome and returned to a national level of competition just one year following his surgery.

According to Dr. LaPrade, PCL reconstruction recovery historically tends to stretch out over time due to the effects of gravity, but the Rebound PCL brace “negates the negative effects of gravity by applying an anterior translation force at higher knee flexion angles,” thereby protecting the PCL graft in early post-op applications.

“Patients with serious multiple ligament knee injuries can be restored back to high levels of activity with modern anatomic-based reconstructions. The additional use of the Rebound PCL brace facilitates a safe initiation of knee motion in the early postoperative period,” he concluded.

Other renowned clinicians who have contributed cases to the Rebound Bracing collection include:

Dr. Mats Brittberg, Professor, Region Halland Orthopedics at Kungsbaca Hospital, Sweden
Dr. Tobias Jung, Senior Physician, Section Head Knee Surgery and Sports Traumatology at Charité-University Medicine Berlin, Germany
Dr. Christos Kondogiannis, Orthopaedic Surgeon at Royal Melbourne Hospital St. Vincent’s Private Hospitals, Australia
Dr. Thomas Stein, Executive Senior Physician in the Department for Sport Traumatology at Berufsgenossenschaftliche Unfalklinik Frankfurt am Main, Germany
Dr. Peter Verdonk, full knee specialist at the Antwerp Orthopaedic Center, Department of Orthopaedic Surgery at Antwerp University Hospital, Netherlands

The full collection of Rebound case studies is available online at https://www.ossur.com/rebound.

“The clinical community’s response to the current line of Rebound braces has been so overwhelmingly positive that we look forward to introducing additional Rebound products in the future, which will complement our Functional Healing products in the continuum of care,” Dr. Schulz said.